Erlotinib Study for Myelodysplastic Syndrome (MDS)
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out what effects, good and/or bad, erlotinib
has on the patient and their myelodysplastic syndrome. Erlotinib has been approved by the
Food and Drug Administration (FDA) to treat non-small cell lung cancer; however, erlotinib
use in this study is considered investigational as the FDA has not approved it for the
treatment of myelodysplastic syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute